Can a vitamin-like pill shield your heart during surgery? new trial aims to find out.

NCT ID NCT07013591

Recruiting now Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a supplement called nicotinamide mononucleotide (NMN) can protect the heart and kidneys of people undergoing coronary artery bypass surgery. Researchers will give NMN or a placebo to 90 adults at higher risk of complications. The main goal is to see if NMN raises levels of a key cell chemical (NAD+) in heart tissue and reduces injury after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nicotinamide mononucleotide (NMN)
What this could lead to: If it works, this could point toward a simple supplement to reduce heart and kidney damage after bypass surgery.
What could go wrong: This is a small, early-phase trial. It only tests if NMN boosts certain cell chemicals, not whether it actually prevents complications. The results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY BYPASS GRAFT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY BYPASS GRAFT

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.